Patents by Inventor Andrea Eicker
Andrea Eicker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10851379Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.Type: GrantFiled: April 25, 2018Date of Patent: December 1, 2020Assignee: BAYER ANIMAL HEALTH GMBHInventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
-
Patent number: 10683508Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.Type: GrantFiled: April 25, 2018Date of Patent: June 16, 2020Assignee: BAYER ANIMAL HEALTH GMBHInventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
-
Patent number: 10155950Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.Type: GrantFiled: February 27, 2015Date of Patent: December 18, 2018Assignee: Bayer Animal Health GmbHInventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
-
Publication number: 20180312842Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.Type: ApplicationFiled: April 25, 2018Publication date: November 1, 2018Inventors: Marcus Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
-
Patent number: 9649374Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: May 16, 2017Assignee: Bayer Intellectual Property GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20160237160Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the TWEAKR (TNFRSF12A, FN14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the TWEAKR. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for us.Type: ApplicationFiled: June 12, 2014Publication date: August 18, 2016Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Christian VOTSMEIER, Stefanie HAMMER, Uwe GRITZAN, Sandra BERNDT, Dmitry ZUBOV, Lars LINDEN, Sven CHRISTIAN, Axel HARRENGA, Jörg BIRKENFELD, Christoph FREIBERG, Sven GOLFIER, Andrea EICKER, Simone GREVEN, Beatrix STELTE-LUDWIG, Marian RASCHKE
-
Patent number: 9241989Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: January 26, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20150267201Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.Type: ApplicationFiled: February 27, 2015Publication date: September 24, 2015Applicant: BAYER ANIMAL HEALTH GMBHInventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
-
Publication number: 20140050743Abstract: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 17, 2012Publication date: February 20, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Frank Dittmer, Anja Buchmüller, Christoph Gerdes, Adrian Tersteegen, Mark Jean Gnoth, Lars Linden, Axel Harrenga, Joanna Grudzinska-Goebel, Mario Jeske, Martina Schäfer, Jörg Birkenfeld, Holger Paulsen, Ricarda Finnern, Anke Mayer-Bartschmid, Andrea Eicker, Simone Greven, Susanne Steinig
-
Publication number: 20130272968Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: October 17, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20130129739Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: May 23, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Ottto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20120321632Abstract: The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: December 20, 2012Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20120237496Abstract: The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta.Type: ApplicationFiled: June 21, 2010Publication date: September 20, 2012Inventors: Joerg Birkenfeld, Andrea Eicker, Per-Ola Freskgard, Claudia Gotzberger-Schad, Joanna Grudzinska, Ulrich Haupts, Josi Innig, Christoph Mahlert, Andreas Scheidig, Michael Strerath, Jan Tebbe, Johan Per-Wallin, Nina Wobst, Carl Innes Webster, Lutz Jermutus